In Silico Drug Repurposing Uncovered the Antiviral Potential of the Antiparasitic Drug Oxibendazole Against the Chikungunya Virus-Reference-Cited by-同舟云学术

In Silico Drug Repurposing Uncovered the Antiviral Potential of the Antiparasitic Drug Oxibendazole Against the Chikungunya Virus

Published:2024-06-13 Issue:25 Volume:9 Page:27632-27642
ISSN:2470-1343
Container-title:ACS Omega
language:en
Short-container-title:ACS Omega

Author:

Rabelo Vitor W.¹^ORCID,Sanchez-Nuñez Maria Leonisa¹,Corrêa-Amorim Leonardo S.¹²,Kuhn Richard J.³⁴^ORCID,Abreu Paula A.⁵,Paixão Izabel C. N. P.¹⁶^ORCID

Affiliation:

1. Programa de Pós-graduação em Ciências e Biotecnologia, Instituto de Biologia, Universidade Federal Fluminense, Niterói, Rio de Janeiro CEP 24210-201, Brazil

2. Gerência de Desenvolvimento Tecnológico, Instituto Vital Brazil, Niterói, Rio de Janeiro 24230-410, Brazil

3. Department of Biological Sciences, Purdue University, West Lafayette, Indiana 47907, United States

4. Purdue Institute of Inflammation, Immunology, and Infectious Disease, Purdue University, West Lafayette, Indiana 47907, United States

5. Instituto de Biodiversidade e Sustentabilidade (NUPEM), Campus Macaé, Universidade Federal do Rio de Janeiro, Rio de Janeiro CEP 27965-045, Brazil

6. Departamento de Biologia Celular e Molecular, Instituto de Biologia, Universidade Federal Fluminense, Niterói, Rio de Janeiro CEP 24210-201, Brazil

Funder

National Institute of Allergy and Infectious Diseases

Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico

Funda??o Carlos Chagas Filho de Amparo ? Pesquisa do Estado do Rio de Janeiro

Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsomega.4c03417

Reference58 articles.

1. Deciphering the dark proteome of Chikungunya virus

2. A Review on Chikungunya Virus Epidemiology, Pathogenesis and Current Vaccine Development

3. Chikungunya, a paradigm of neglected tropical disease that emerged to be a new health global risk

4. New global targets for NTDs in the WHO roadmap 2021–2030

5. Global geotemporal distribution of chikungunya disease, 2011–2022